ArticleBMC infectious diseases2014
Serum biomarkers predictive of cure in Chagas disease patients after nifurtimox treatment.
Article in BMC infectious diseases, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 50 citations in OpenAlex.
- Serum Proteomics Provides Novel Biomarkers of Inflammation, Tissue Injury, and Therapeutic Response in Experimental Chagas Disease.Microorganisms · 2026Article
- Evaluation of Apolipoprotein-A1 genetic polymorphisms as biomarkers for Chagas cardiomyopathy in patients from Córdoba, Argentina.Molecular biology reports · 2025Observational
- Intra-hostMicrobiology spectrum · 2023Article
- Proteomics investigation of human sera for determination of postoperative indicators of pulmonary cystic echinococcosis.Journal of cardiothoracic surgery · 2023Article
- New metabolic signature for Chagas disease reveals sex steroid perturbation in humans and mice.Heliyon · 2022Article
- Fibronectin degradation as biomarker forParasitology · 2021Article
- Cytotoxicity of Essential OilMolecules (Basel, Switzerland) · 2021Article
- Proteomic Insights into the Biology of the Most Important Foodborne Parasites in Europe.Foods (Basel, Switzerland) · 2020Review
- Review
- Target product profile for a test for the early assessment of treatment efficacy in Chagas disease patients: An expert consensus.PLoS neglected tropical diseases · 2020Article
- A Parasite Biomarker Set for Evaluating Benznidazole Treatment Efficacy in Patients with Chronic Asymptomatic Trypanosoma cruzi Infection.Antimicrobial agents and chemotherapy · 2019Article
- Validation of Apolipoprotein A-1 and Fibronectin Fragments as Markers of Parasitological Cure for Congenital Chagas Disease in Children Treated With Benznidazole.Open forum infectious diseases · 2018Article
- A novel antibody surrogate biomarker to monitor parasite persistence in Trypanosoma cruzi-infected patients.PLoS neglected tropical diseases · 2018Article
- The Trypomastigote Small Surface Antigen from Trypanosoma cruzi Improves Treatment Evaluation and Diagnosis in Pediatric Chagas Disease.Journal of clinical microbiology · 2017Article
- Biosensors to Diagnose Chagas Disease: A Brief Review.Sensors (Basel, Switzerland) · 2017Review
- Chagas disease research and development: Is there light at the end of the tunnel?Computational and structural biotechnology journal · 2017Review
- Chagas Disease Diagnostic Applications: Present Knowledge and Future Steps.Advances in parasitology · 2017Review
- Article
- Scrutinizing the Biomarkers for the Neglected Chagas Disease: How Remarkable!Frontiers in immunology · 2016Review
- Identification of Candidate Serum Biomarkers for Schistosoma mansoni Infected Mice Using Multiple Proteomic Platforms.PloS one · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundChagas disease (CD), caused by the protozoan Trypanosoma cruzi, remains an important public health issue in many Central and South American countries, as well as non-endemic areas with high rates of immigration from these countries. Existing treatment options for CD are limited and often unsatisfactory. Moreover the lack of post-treatment tests of cure limits the development of new drugs. To address this issue, we sought to identify serum biomarkers following nifurtimox (Nfx) treatment that could be used as an early test of cure and/or markers of a therapeutic response.
methodsHuman sera from Chagas patients pre- and post-treatment with Nfx (n = 37) were compared to samples from healthy subjects (n = 37) using a range of proteomic and immunologic techniques. Biomarker peaks with the best discriminatory power were further characterized.
resultsUsing serum samples (n = 111), we validated the presence of five key biomarkers identified in our previous study, namely human apolipoprotein A-I (APOA1) and specific fragments thereof and one fragment of human fibronectin (FN1). In chagasic serum samples all biomarkers except full-length APOA1 were upregulated. These five biomarkers returned to normal in 43% (16/37) of the patients treated with Nfx at three years after treatment.
conclusionsThe normalization of biomarker patterns strongly associated with CD suggests that these markers can be used to identify patients in whom Nfx treatment is successful. We believe that these are the first biomarkers predictive of cure in CD patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.